OpGen, Inc. (OPGN)

Market Cap	3.52M
Revenue (ttm)	3.42M
Net Income (ttm)	-32.67M
Shares Out	1.34M
EPS (ttm)	-41.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,682
Open	2.510
Previous Close	2.510
Day's Range	2.500 - 2.620
52-Week Range	1.650 - 38.400
Beta	-0.66
Analysts	Hold
Price Target	n/a
Earnings Date	Aug 8, 2024

About OPGN

OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. OpGen, Inc. was incorporated in 2001 and is headquartered in Rockville, Maryland.

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 5, 2015
• Employees: 85
• Stock Exchange: NASDAQ
• Ticker Symbol: OPGN

Financial Performance

In 2023, OpGen's revenue was $3.42 million, an increase of 31.11% compared to the previous year's $2.61 million. Losses were -$32.67 million, -12.38% less than in 2022.